Clinical Outcomes of a Monofocal, Optimized, Aspheric, Hydrophobic Acrylic Intraocular Lens Implant

Abstract

Purpose

To evaluate the refractive and visual outcomes of eyes implanted with monofocal, optimized, aspheric, hydrophobic acrylic intraocular lenses (IOL) following cataract surgery.

Methods

The study assessed 55 eyes implanted with CT LUCIA^® 621P IOLs (Carl Zeiss Meditec AG, Jena, Germany) at 3-months postsurgery. The main outcome measures were refractive error, monocular corrected distance visual acuity (CDVA), monocular uncorrected distance visual acuity (UDVA), photopic and mesopic contrast sensitivity, and wavefront aberrations. Patients were asked to complete the Catquest-9SF questionnaire.

Results

At 3 months, the cumulative Snellen visual acuity was 20/20 in 94.55% of eyes and 20/25 or better in 100%. The difference between the UDVA and CDVA was either the same (70.91%) or better (29.09%) in all eyes. The mean Snellen decimal UDVA and DCVA were 1.07 ± 0.15 and 1.13 ± 0.11, respectively. The safety and efficacy indexes were 1.48 and 1.40, respectively. 47.27% of eyes showed a spherical equivalent ±0.13 D, with 92.73% of the eyes were within ±0.50 D and all eyes were within ±1.00 D. The mean spherical equivalent was −0.03 ± 0.30 D and the mean refractive cylinder −0.36 ± 0.34 D. The log photopic and mesopic contrast sensitivity functions were good and similar for all spatial frequencies. All patients reported being either fairly satisfied (score 3) or very satisfied (score 4) with their vision (mean = 3.64 ± 0.49). No intra- and postoperative complications were reported during the 3 months of follow-up.

Conclusion

The current study demonstrates that excellent visual and refractive outcomes, as well as patient satisfaction, can be achieved after cataract surgery with optimized, aspheric CT LUCIA 621P monofocal IOLs.

Keywords:

• cataract
• intraocular lens
• aspheric
• aberrations
• contrast sensitivity
• phacoemulsification

Data Sharing Statement

The data are not available for sharing.

Disclosure

Dr Berta García-Tomás reports grants from Carl Zeiss Meditec, Inc., outside the submitted work. The authors report no other conflicts of interest in this work.

Additional information

Funding

This study was funded by an investigator-sponsored study from Carl Zeiss Meditec, Inc. Carl Zeiss did not have any role in the study design, data collection and analysis, decision to publish, and preparation of the manuscript.